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Furosemide kinetics and dynamics after kidney transplant 
We examined differences between responder (R) (40 to 80 mg/day) and nonresponder (NR) 
( 120 mg/day) patients after kidney transplant with respect to furosemide kinetics and 
dynamics. Nonresponders had reduced plasma clearance (NR 64 ± 21.4 and R 105 ± 23 
ml/min, two-sample t test; p < 0.05), renal clearance (NR 18.4 ± 8.1 and R 47.1 ± 11.0 
ml/mm; p < 0.005), and renal clearance to creatinine clearance ratio (NR 0.43 ± 0.15 and R 
0.80 ± 0.07; p <0.005). Half-life rose in the nonresponders (NR 130 ± 13 and R 
87.6 ± 16.3 min; p < 0.005). There was no difference between groups with respect to nonrenal 
clearance, extent of availability, volume of distribution steady state, and the .fraction of the dose 
excreted unchanged in the urine after intravenous administration. These results suggest that 
nonresponders have less ability to secrete fitrosemide into tubular fluid as well as less ability to 
respond to drug. 
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Furosemide is one of the most potent diuretics 
available today. .19' 29. 31 It exerts its effect at the 
luminal surface of the nephron where it inhibits 
the active reabsorption of chloride in the ascend- 
ing limb of the loop of Henle.8' 9' 16' 27 Because 
furosemide is highly protein bound,2' 25 access to 
the kidney lumen occurs primarily through active 
secretion through the nonspecific organic acid 
secretory pathway. 13Thus any drug or disease 
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that prevents furosemide from reaching its site of 
action in the lumen could attenuate its natriuretic 
and diuretic action. 
Furosemide is a valuable diuretic after kidney 
transplant in treatment of volume overload. 
Cumulation of extracellular fluid is common, 
usually occurring soon after transplantation, 
and may persist for months despite the absence 
of conditions usually associated with salt and 
water retention such as acute rejection of the 
transplant, congestive heart failure, hypoal- 
buminemia, and low glomerular filtration rate. 
Clinical observations* suggest that, although 
after kidney transplant some patients respond 
well to small doses of furosemide (responders), 
others (nonresponders) are refractory to the 
drug. In nonresponders larger doses of 120 mg or 
more may be needed to mobilize edema. After 
*F. Vincenti: Unpublished observations. 
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Table I. Patient characteristics 
*Creatinine clearance was determined over 24 hr. 
kidney transplant, patients seem to respond better 
to intravenously administered doses of furose- 
mide than to equivalent doses orally. 
Although furosemide is widely used after 
kidney transplant, its disposition and dose- 
response relationship have not been studied, 
and dosage reigmens continue to be empiric. 
Our investigation was undertaken (1) to study 
furosemide kinetics after kidney transplant in 
patients after doses orally and intravenously, (2) 
to determine whether intravenous administra- 
tion of furosemide is more efficacious in these 
patients than equal doses orally, and (3) to de- 
termine whether there are differences between 
responders (R) and nonresponders (NR) after 
kidney transplant with respect to furosemide ki- 
netics and dynamics. 
Methods 
Materials. Furosemide tablets (40 mg) and 
intravenous solution (10 mg /m1), sodium phe- 
nobarbital, glass-distilled acetonitrile (Burdick 
and Jackson), and analytic reagent-grade phos- 
phoric acid (Mallinckrodt) were used. 
Patient studies. Characteristics of the nine 
patients studied are listed in Table I. Patients (five 
men, four women) ranged in age from 25 to 56 yr 
(R. 41 yr) and in weight between 65.5 and 95.2 kg 
(5-( 76.5 kg). Creatinine clearance ranged from 
30.1 to 88.1 ml/min (K 52.4 ml/ min), and serum 
albumin and plasma electrolyte levels were nor- 
mal. No subject had congestive heart failure 
(CHF), diabetes, nephrotic syndrome, or liver 
disease, except patient C. T., who had mild CHF. 
Patients were titrated to and studied at a dose 
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C. T. 45 95.2 Nephrosclerosis 30.1 Prednisone, azathioprine, 
prazosin, calcium gluco- 
nate, bethanechol, min- 
oxidil, aminophylline, 
isosorbide, metapro- 
terenol 
E. H. M 53 89.5 Glomerulonephritis 61.5 Prednisone, cyclophospha- 
mide, propranolol, cloni- 
dine 
D. H. F 25 65.5 Glomerulonephritis 37.3 Prednisone, azathioprine, 
cimetidine, hydralazine, 
propranolol 
L. T. M 31 68.5 Nephrosclerosis 41.7 Prednisone, azathioprine, 
cephradine, flurazepam, 
pseudoephedrine 
V. W. F 56 66.7 Glomerulonephritis 46.9 Prednisone, azathioprine, 
clonazepam, propran- 
olol, isosorbide, diaze- 
pam, penicillin VK 
S. J. F 31 75.8 Glomerulonephritis 50.2 Prednisone, azathioprine, 
sulfisoxazole 
P. D. M 48 67.1 Glomerulonephritis 68.0 Prednisone, azathioprine, 
sulfisoxazole, bethane- 
chol 
W. J. F 35 68.9 Glomerulonephritis 88.1 Prednisone, azathioprine, 
diazepam 
F. R. M 44 91.3 Unknown 47.7 Prednisone, azathioprine, 
flurazepam, sulfisoxa- 
zole, propranolol, nitro- 
glycerin, acetaminophen 
Mean 41 76.5 52.4 
(SD) (11) (12.1) (17.7) 
Age Weight Cause of CLcr* 
Patient Sex (yr) (kg) renal failure (ml/mm) Concomitant drugs 
Volume 30 
Number I 
3000 
c`= 2000 
capable of inducing an adequate response. Re- 
sponders included those transplant patients who 
had an adequate natriuretic and diuretic response 
to a lower range of doses of furosemide (e.g. , 40 
to 80 mg). Nonresponders were more refractory 
and required 120 mg or more of furosemide for an 
adequate response. Although patient S. J. was 
studied at doses of 120 mg furosemide, she was 
assigned to group R because of her extensive 
natriuretic and diuretic output at this dose, with a 
weight loss of 3.2 kg after doses orally. She also 
had a substantial response with a 40 mg dose of 
furosemide orally. 
After an overnight fast each subject received a 
dose of furosemide either orally or intravenously 
at approximately 8:00 A.M. Furosemide was 
taken with water or fruit juice, and patients 
fasted for at least 2 hr after the dose orally. The 
solution was infused intravenously over 10 min. 
Blood samples (3 ml) after doses intravenously 
were obtained by an indwelling heparinized 
scalp vein needle at 0, 10, 15, 20, 30, 45, 60, 80, 
100, 120, 180, 240, 360, 480, and 1440 min, the 
end of the infusion period being 10 min. After 
doses orally blood samples were drawn at 0, 15, 
30, 45, 60, 75, 90, 105, 120, 180, 240, 360, 
480, and 1440 min. Voided urine was collected 
just before furosemide, hourly up to 8 hr, and 
then pooled for from 8 to 24 hr. Urine collection 
times differed depending on patient ability to 
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Fig. 1. Relationship between urine volume and sodium excretion in patients after kidney transplant. 
void. Furosemide studies were carried out on 
consecutive days after doses orally and intrave- 
nously. 
Preparation of standard solutions. Furo- 
semide, 4.1 mg, was dissolved in acetonitrile to 
make a stock solution of 41 Ag/ml. This stock 
solution was then diluted fivefold (8.2 iug/m1) 
and 100-fold (0.41 ,ug/m1) to make working 
standard solutions. Sodium phenobarbital was 
dissolved in distilled water at concentrations 
ranging from 0.05% to 1%, depending on the 
concentration range of furosemide to be ana- 
lyzed in the samples. 
Measurement of furosemide in plasma and 
urine. Plasma and urine samples containing 
furosemide were analyzed as described by 
us" with minor modifications. Samples were 
pumped through a juBondapak C18 reversed- 
phase column (30 cm x 3.9 mm i.d.) by a Var- 
ian Model 5000 Liquid Chromatograph, and 
furosemide was quantified using a Perkin-Elmer 
Fluorescence Spectrophotometer 650-10S. The 
excitation and emission wavelengths of furo- 
semide were set at 345 and 405 nm. The internal 
standard, sodium phenobarbital, was measured 
by ultraviolet detection (254 nm) using a Waters 
Associates Model 440 absorbance detector. A 
50-p,1 aliquot containing the internal standard, 
sodium phenobarbital (0.05%), was added to 
0.20-ml furosemide plasma samples. The mix- 
108 Smith et al. 
Table II. Furosemide kinetics in patients after kidney transplant 
Level of significance between responders (R) and nonresponders (NR). 
No difference was found between oral and intravenous administration of furosemide in R and NR. 
*p <0.01. 
tp <0.001. 
#13 < 0.05. 
§p < 0.005. 
IlDetermined from the residual slope of the feathered oral plasma curve (see Discussion). 
ture was shaken on a vortex mixer, and 0.40 ml 
acetonitrile was added. The mixture was shaken 
again on a vortex mixer and then centrifuged for 
10 min. The supernatant was transferred to a 
clean test tube and evaporated under nitrogen 
until about 0.10 ml solution remained. Urine 
samples were prepared similarly, but no 
acetonitrile was added and the evaporation step 
was omitted. A 50-/L1 aliquot containing the in- 
ternal standard, sodium phenobarbital (1.0%), 
was added to 0.05-ml furosemide urine samples 
and 0.20 ml distilled water. The mixture was 
shaken on a vortex mixer, and an aliquot was 
introduced directly into the loop injector. At a 
flow rate of 2 ml/min furosemide and sodium 
phenobarbital had retention times of 6 and 4 min 
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in a 38% acetonitrile-0.015 M phosphoric acid 
solvent system. The detection limit of furo- 
semide in plasma under the described assay con- 
ditions is 8 ng/ml with a peak to noise ratio of 5. 
Chlorpromazine (0.02%) was substituted as the 
internal standard in patients taking sulfis- 
oxazole, because sodium phenobarbital and 
sulfisoxazole have similar retention times and 
interfere with each other. Under conditions 
identical to those described above, chlor- 
promazine was measured by UV detection (254 
nm) and had a retention time of 8.5 min. 
Measurement of sodium. Urine samples con- 
taining sodium were analyzed by Corning Model 
450 flame photometer.29 Sodium concentrations 
were not measured for patient V. W. because 
Patient Status Treatment 
CLp 
(ml/min) 
Vdss 
(mIlkg) 
T1/2 
(min) 
CLr 
(ml/mm) 
C. T. NR 160 mg po 138 10.8 
160 mg iv 60.4 77.5 138 10.7 
E. H. NR 120 mg po 120 22.1 
120 mg iv 84.6 110.0 116 23.0 
D. H. NR 120 mg po 174 10.3 
120 mg iv 35.6 92.9 143 12.4 
L. T. NR 120 mg po 137 23.8 
120 mg iv 75.4 167.0 122 27.4 
Mean NR po 142* 16.8$ 
(SD) (23) (7.2) 
Mean NR iv 64.0$ 112 130§ 18.4§ 
(SD) (21.4) (39) (13) (8.1) 
V. W. 80 mg po 70.5 45.9 
80 mg iv 80.5 102.0 99.8 35.1 
S. J. R 120 mg po 74.911 43.5 
120 mg iv 122 173.0 74.5 41.0 
P. D. R 40 mg po 85.0 65.6 
40 mg iv 135 127.0 66.4 54.2 
W. J. R 80 mg po 89.5 66.7 
80 mg iv 88.1 83.5 93.1 62.4 
F. R. R 80 mg po 119.0 50.4 
80 mg iv 98.9 95.1 104.0 42.8 
Mean R po 87.8* 54.4t 
(SD) (19.0) (11.0) 
Mean R iv 105$ 116 87.6§ 47.1§ 
(SD) (23) (36) (16.3) (11.0) 
Volume 30 
Number 1 
the samples were lost. An estimate of urinary 
sodium was therefore made for her based on the 
strong correlation between sodium excretion and 
urine output in the other eight patients (Fig. 1; 
r = 0.981, p <0.001). 
Calculations. The furosemide half-life (t1/2) 
was determined by linear regression using at 
least four data points from the terminal portion 
of the plasma versus time plots. The area under 
the plasma concentration time curve (AUC) was 
calculated by the trapezoidal rule, extrapolated 
to infinity from the last measured concentration. 
The absolute bioavailability (F) was calculated 
using both plasma (Fp) and urine (Fu) data: 
Fp = AUCorai/AUC,v and Fu = Aeorai/Ae 
where the amount of unchanged drug recovered 
in the urine at time infinity is represented by 
Ae'. In our study the reported F represents the 
averaged availability of Fp and Fu. Total plasma 
clearance of intravenously administered furo- 
semide (CLp) was calculated as CLp = dose/ 
AUC. Total renal clearance (CLr) was estimated 
after doses intravenously and orally by CLr = 
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Ae'/AUC. The fraction of the furosemide dose 
intravenously that was excreted unchanged in 
the urine (fe) was calculated as fe = Ae'/Dose. 
Nonrenal plasma clearance (CLnr) was calcu- 
lated as the difference between the plasma and 
renal clearances. The volume of distribution 
steady state ( Vd) was determined from the in- 
travenous plasma data by the compartment in- 
dependent method of Benet and Galeazzi6 cor- 
rected for infusion administration: 
Dose (AUMC) 7-Dose Vdss = 
(AUC)2 2 (AUC) 
where AUMC is the area under the curve of the 
first moment of the concentration time curve 
(i.e., f tCpdt) and T is the infusion time. 
Data throughout the study are expressed as 
-± SD. Statistical differences between groups 
R and NR were determined using a two-sample 
t test. Statistical differences between treat- 
ments given orally and intravenously within 
groups R and NR were determined by a paired 
t test. 
Results 
The kinetic data on furosemide administered 
orally and intravenously in patients after kidney 
transplant are presented in Table II. The volume 
of distribution steady state did not differ be- 
tween responders and nonresponders (R 116 ± 
36 and NR 112 ± 39 ml/kg; p >0.50) and 
was in good agreement with data published 
by our group in healthy subjects." " Non- 
responders had a reduced plasma clearance (NR 
64.0 ± 21.4 and R 105 -± 23 ml/min; p < 
0.05) and renal clearance (NR 18.4 -± 8.1 and 
R 47.1 ± 11.0 ml/min; p <0.005), but non- 
renal clearance did not differ from responders 
(NR 45.6 -± 16.1 and R 57.8 ± 23.7 ml/min; 
p > 0.20). T1/2 in responders was of the same 
order as in healthy subjects29 but were lower 
than in the nonresponders (R 87.6 -± 16.3 and 
NR 130 ± 13 min; p < 0.005). Although the 
fraction excreted unchanged in the urine after 
intravenous administration was approximately 
37% lower in nonresponders, the magnitude of 
this change was no different (NR 0.290 
0.086 and R 0.463 ± 0.143; p > 0.05). There 
was no difference in the extent of absorption 
orally between responders and nonrespond- 
CLnr 
(ml/mm) fe (%) 
CLr 
CLcr 
0.36 
49.7 0.176 74.6 0.36 
0.36 
61.6 0.272 30.4 0.37 
0.28 
23.3 0.348 81.6 0.33 
0.57 
48.0 0.363 42.4 0.66 
0.39t 
(0.12) 
45.6 0.290 57.2 0.43§ 
(16.1) (0.086) (24.7) (0.15) 
0.98 
45.4 0.436 53.0 0.75 
0.87 
81.0 0.336 38.6 0.82 
0.96 
80.8 0.402 48.2 0.80 
0.76 
25.7 0.709 54.4 0.71 
1.06 
56.1 0.432 55.3 0.90 
0.93t 
(0.11) 
57.8 0.463 49.9 0.80§ 
(23.7) (0.143) (6.9) (0.07) 
110 Smith et al. 
Table LII. Furosemide dynamics in patients after kidney transplant 
*Level of significance p < 0.05. 
tDerived from linear re ression analysis in Fig. I. 
tValues not included in the mean (SD) data. 
ers (R 49.9 ± 6.9 and NR 57.2 ± 24.7%; 
p > 0.50) as well as in our data in healthy sub- 
jects." When renal clearance was corrected for 
kidney function (as determined by creatinine 
clearance) there were clear differences between 
responders and nonresponders (R 0.80 ± 0.07 
and NR 0.43 ± 0.15; p <0.005). 
Furosemide dynamics in patients after kidney 
transplant following oral and intravenous ad- 
ministration as well as the amount of furose- 
mide excreted unchanged in the urine after 
both treatments are presented in Table III. 
Nonresponders had reduced sodium excretion 
after furosemide orally (NR 76.4 ± 44.2 and 
R 205 ± 97 mEq/8 hr; p < 0.05), although 
equivalent amounts of unchanged drug were 
excreted in the urine (NR 19.8 ± 8.9 and R 
19.8 ± 8.6 mg; p > 0.50). Urine volume after 
furosemide orally was also less in nonre- 
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sponders but not statistically significantly so 
(NR 996 -± 377 and R 1869 ± 730 m1/8 hr; 
0.10 > p > 0.05); but after intravenous admin- 
istration there was no difference between re- 
sponders and nonresponders with respect to 
furosemide-induced natriuresis (R 184 ± 19 
and NR 145 ± 68 mEq/8 hr; p > 0.20), di- 
uresis (R 1727 ± 202 and NR 1546 _± 449 
m1/8 hr; p > 0.20), and amount excreted un- 
changed in the urine (R 36.5 ± 14.5 and NR 
36.6 ± 7.4 mg; p > 0.50). 
Discussion 
The therapeutic efficacy of furosemide varies 
widely among patients with different degrees of 
renal impairment. t, 21, 22 The ability of patients 
after kidney transplant to respond to furosemide 
is unpredictable, and larger doses are often 
needed to induce adequate diuresis and natri- 
Patient Status Treatment 
Sodium excretion 
(mEq18 hr) 
Urine volume 
(Ml /8 hr) Ae" (mg) 
C. T. NR 160 mg po 77.8 1185 21.2 
160 mg iv 77.4 1129 28.2 
E. H. NR 120 mg po 25.5 489 9.7 
120 mg iv 116.0 1277 32.6 
D. H. NR 120 mg po 69.2 949 31.0 
120 mg iv 151.0 1644 41.8 
L. T. NR 120 mg po 133.0 1360 17.2 
120 mg iv 237.0 2136 43.6 
Mean NR po 76.4* 996 19.8 
(SD) (44.2) (377) (8.9) 
Mean NR iv 145 1546 36.6 
(SD) (68) (449) (7.4) 
V. W. 80 mg po 118t 1278 21.8 
80 mg iv 167t 1627 34.9 
S. J. 40 mg po 145$ 1353$ 5.31: 
120 mg po 322 2686 16.1 
120 mg iv 185 1717 40.3 
P. D. 40 mg po 125 1108 8.5 
40 mg iv 163 1456 16.1 
W. J. 80 mg po 296 2579 31.9 
80 mg iv 204 1854 56.7 
F. R. 80 mg Po 164 1695 20.7 
80 mg iv 203 1979 34.6 
Mean po 205* 1869 19.8 
(SD) (97) (730) (8.6) 
Mean iv 184 1727 36.5 
(SD) (19) (202) (14.5) 
Volume 30 
Number I 
uresis. Mechanisms that may explain the resis- 
tance to furosemide include reduced bioavail- 
ability, changes in drug metabolism, decreased 
glomerular filtration rate, and reduction in renal 
tubular transport. 
In healthy subjects renal clearance of furo- 
semide is about 120 ml/min4' 29' 39 and the frac- 
tion of the dose excreted unchanged in the urine 
about 60% to 75%.4' 7' 29' 39 We found that the 
renal clearance for the nine patients ranged from 
10.3 to 66.7 ml/min, which was 0.086 to 0.56 
that of healthy subjects, but there were marked 
differences between responders and nonre- 
sponders with respect to renal clearances alone 
as well as when corrected for kidney function. 
Mean corrected renal clearances (CLr/CLcr) for 
the nonresponders (0.43 ± 0.15) were approx- 
imately half the values for responders (0.80 ± 
0.07). Because furosemide is over 95% protein 
bound in plasma,2-4, 24, 25, 30 glomerular filtra- 
tion contributes minimally to its total renal 
clearance. Thus attenuated renal clearance of 
furosemide suggests impairment in the secre- 
tory component of the organic acid transport 
system. Such depression in renal transport can 
affect urinary excretion rate of furosemide, 
which has been shown to be the critical deter- 
minant with respect to diuretic and natriuretic 
effect. 11, 26, 28, 29 
In our study the attenuated renal clearance in 
nonresponders necessitates larger doses of furo- 
semide to achieve equivalent unchanged drug in 
urine and therefore an equivalent dynamic ef- 
fect to that of responders. This is shown in 
Table III, where responders and nonresponders 
have virtually identical amounts of unchanged 
furosemide in the urine after doses intravenous- 
ly, and also by a similar response between the 
two groups. After furosemide orally, however, 
nonresponders have less natriuresis than re- 
sponders, although both groups ultimately ex- 
crete identical amounts of unchanged drug in 
the urine. Although speculative, it is possi- 
ble that the "critical" luminal concentration 
amount of furosemide needed for an adequate 
dynamic effect is higher in nonresponders such 
that this "critical" level is reached after doses 
intravenously but not orally. This may explain 
the apparent discrepancy in the differences in 
natriuresis and diuresis between responders and 
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Fig. 2. Furosemide plasma concentration:time plot 
in patient S. J. after oral (40 and intravenous (N) 
administration of furosemide. (0), residual slope of 
the feathered oral curve. 
nonresponders after doses orally but not intra- 
venously. 
Although there is a trend toward reduced bio- 
availability of furosemide in patients with renal 
impairment,5 this has not been a factor in di- 
uretic resistance. '7 However, a recent case re- 
port23 shows that apparent resistance to furo- 
semide orally can be explained by reduced bio- 
availability in the edematous as opposed to the 
nonedematous state. We found similar values 
for bioavailability in responder and non- 
responder patients after kidney transplant as 
well as in healthy subjects.5 Therefore change 
in the extent of oral absorption is not a viable 
explanation for its reduced effectiveness after 
kidney transplant. 
Reports on healthy subjects,7. 18 patients with 
heart failure,'2 and "diuretic-resistant" pa- 
tients '7 demonstrated that an equivalent diuretic 
response to furosemide was achieved whether 
the dose was given by mouth or by intravenous 
SLOPE = 030038 
MIN-1 
SLITE =0.3893 
MIN-1 
\., 
\., 
SLOPE = 0.0092 
MIN-1 
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injection. In uremic patients Huang et al." 
found the diuresis induced by furosemide orally 
was always less effective than after doses intra- 
venously. This also appeared to be the case in 
our study when average sodium and water ex- 
cretion values after doses orally and intrave- 
nously are compared for nonresponders but not 
for responders. The individual results in Table 
III demonstrate considerable variability in the 
natriuretic and diuretic response of patients after 
kidney transplant to furosemide orally and in- 
travenously. Factors such as uncontrolled fluid 
intake and lack of electrolyte-water replacement 
may have contributed to this variability, but a 
more controlled study was not ethically possible 
because of the clinical condition of the patients. 
Our studies were carried out as the drug is used 
clinically. 
An unusual plasma concentration : time pro- 
file of furosemide was observed in patient S. J., 
in whom the terminal slopes after doses orally 
and intravenously were not similar (Fig. 2). On 
feathering the oral curve the residual slope was 
virtually identical to that of the terminal slope 
after intravenous administration of furosemide. 
This is indicative of a "flip-flop" model in 
which the elimination of the drug is rate limited 
by its absorption. In addition, intersection of the 
terminal and residual slopes of the oral curve at 
some point in time above zero suggests lag time 
before absorption. In this case there was a lag 
time of about 50 mm, with a peak furosemide 
concentration in plasma not reached until 4 hr 
after dosing orally. Delayed absorption of 
furosemide such as in patient S. J. may also be 
present in other patients after kidney transplant, 
perhaps to a lesser degree, and contributes to 
the unpredictability of assessing diuretic and 
natriuretic response to furosemide. 
A recent study15 reported furosemide to have 
a t1/2 of about 4 days in a 39-year-old patient 
studied postoperatively for 26 days. During the 
first 10 days after kidney transplantation the pa- 
tient lost 172 1 urine. The authors speculated 
that this massive diuresis may have been caused 
by a depot effect of furosemide in which the 
drug cumulated in body tissues during high- 
dose furosemide treatment before transplanta- 
tion. In our study patients were studied at least 
Clin. Pharmacol. Ther. 
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18 days after surgery. The mean furosemide t1/2 
in responders and nonresponders was 87.6 and 
130 min, in sharp contrast to the 4-day t1/2 re- 
ported '5 and would argue against a similar depot 
effect being present in our nine patients. 
Our results imply that after kidney transplant 
nonresponders have less ability to secrete furo- 
semide into tubular fluid as well as less ability 
to respond to equivalent amounts of drug ex- 
creted in the urine. Furosemide intravenously 
offers no real advantages over oral drug for 
continued therapy. 
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